In this blog post, we’ll examine how HIV utilizes a cell’s genetic information and why a cure remains elusive, and explore how a virus’s ability to deliver genetic material is being transformed into a technology for treating diseases.
- From the Ability to Infect Cells to a Therapeutic Tool
- The Process by Which DNA Information Becomes Protein
- HIV deposits its genetic information into the cell’s DNA
- Viral genetic information can persist even if replication is blocked
- Harnessing the Ability to Persistently Retain Genetic Information for Treatment
From the Ability to Infect Cells to a Therapeutic Tool
A virus’s ability to deliver genetic material into a cell is the starting point of infection. But what if we could alter the genetic information being delivered? If we were to send information necessary for treatment instead of the information required for the virus to replicate, we could help cells produce missing proteins or develop the ability to fight disease. The gene delivery tool developed based on this concept is the “viral vector.” Here, a vector refers to a carrier that delivers genetic material into cells.
The human immunodeficiency virus (HIV) is a case that illustrates both the potential and the challenges of this concept. HIV infects cells such as CD4 T cells, which aid in the immune response, and if left untreated, can severely damage the immune system. Acquired immunodeficiency syndrome (AIDS) is a condition in which HIV infection has progressed to the point where immune function is significantly compromised or specific diseases have developed, meeting diagnostic criteria. Therefore, HIV infection and AIDS are not the same thing.
According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), an estimated 41 million people worldwide will be living with HIV by 2025. However, HIV infection should not be understood solely as an incurable disease. By suppressing viral replication through antiretroviral therapy, progression to AIDS can be prevented, allowing people to live healthy lives for a long time. It is important to distinguish between treatment that suppresses the virus and a cure that completely eliminates the virus from the body. While effective treatments exist for HIV, a cure that can be widely applied to people living with the virus has not yet been established. To understand why, we first need to examine how cells use genetic information.
The Process by Which DNA Information Becomes Protein
Within cells, proteins perform various functions. They form the cell’s structure, catalyze chemical reactions, transmit signals, and participate in immune responses. For a cell to function properly, it must produce the necessary proteins in the right amounts at the right time. DNA contains the information for making these proteins as well as the information that regulates their production.
The genetic information for protein synthesis is generally transmitted from DNA to RNA and then to the protein. First, a process called “transcription” occurs, in which RNA is synthesized based on a specific segment of DNA. Next, a cellular structure called a ribosome reads the information contained in messenger RNA (mRNA), which is used for protein synthesis. The ribosome links amino acids—the building blocks of proteins—in sequence according to this information. This process is called “translation.” However, not all RNA serves as an intermediate step in protein synthesis. RNA can also function directly, such as by forming structures or regulating the activity of other genes.
If we compare a cell to a factory, DNA is the manual that stores manufacturing instructions and production control information, while mRNA is the work instruction sheet retrieved to make a specific product. The ribosome corresponds to the production machinery that reads that instruction sheet and synthesizes proteins. Most nucleated somatic cells in a person’s body generally share the same genetic information, but the information each cell uses differs. The reason nerve cells and muscle cells perform different functions is that they utilize different information from the same manual.
Of course, this analogy does not mean that DNA alone can explain all the characteristics of a living organism. Gene activity varies depending on signals and the environment inside and outside the cell, and protein production is regulated at various stages. A change in DNA does not necessarily result in the production of harmful proteins. Depending on the location and nature of the change, the effect may be negligible, or the protein’s function or production level may change.
HIV deposits its genetic information into the cell’s DNA
HIV is a retrovirus that uses RNA as its genetic material. Once inside a cell, HIV uses “reverse transcriptase” to convert its RNA into DNA. Since this process—in which RNA is produced from DNA—runs in the opposite direction of normal transcription, it is called “reverse transcription.” The viral DNA produced in this way is inserted into the host cell’s DNA by the action of “integrase.” A host refers to an organism or cell that is infected and utilized by the virus, and the viral DNA integrated into the cell’s DNA is called a “provirus.”
When the provirus is activated, viral RNA and proteins are produced using the cell’s transcription and translation machinery. As these components assemble and mature, new infectious viruses are formed. Continuing the factory analogy from earlier, it is as if information on how to make viruses has been added to the existing manual, and the production machinery has been programmed to read that information as well.
This does not mean that the cell recognizes the viral DNA as its own or consciously obeys the virus’s commands. It is a phenomenon that occurs because the virus’s genetic information can be read and utilized by the cell’s molecular machinery. Nor does the entire genetic information of the infected cell change into viral information. Rather, viral information is added to the existing genome—that is, the cell’s entire DNA.
While all viruses use host cells for replication, not all follow the same process as HIV. A defining characteristic of retroviruses is their ability to convert RNA into DNA and integrate that DNA into the host genome. This ability—which allows viral genetic information to persist within the cell for a long time—is both the reason why a cure for HIV is difficult to achieve and a property that researchers seek to harness in gene delivery technologies.
Viral genetic information can persist even if replication is blocked
One of the key reasons a cure for HIV is difficult to achieve is the “latent reservoir.” In some infected cells, viral DNA remains in the genome without actively producing new viruses. These cells serve as a base from which the virus can resume replication. Infected cells can survive for a long time, and some even pass the viral DNA on to newly formed cells as they divide.
Antiretroviral drugs block the steps necessary for viral replication, such as reverse transcription and integration. As a result, they suppress the spread of infection to new cells and help preserve immune function. However, they cannot completely eliminate all viral genetic material that has already integrated into the cell’s DNA and lies dormant. If treatment is discontinued, this genetic material can be reactivated, allowing viral replication to resume. In other words, preventing viral production and eliminating the genetic material capable of producing the virus are two distinct challenges.
The difficulty lies not only in the fact that the viral DNA is located inside the cell nucleus. Latently infected cells produce almost no viral proteins, making them difficult for the immune system to detect, and they are hard to eliminate even with drugs that target the viral replication process. This does not mean that infected cells cannot be distinguished at all. Rather, it means that it is difficult to locate and safely eliminate every single latently infected cell remaining in various parts of the body, or to prevent the viruses within them from becoming active again.
Therefore, the achievements and limitations of HIV treatment must be viewed together. Treatment that suppresses viral replication to protect health is already possible. Preventing the virus from replicating again after treatment is discontinued is the next challenge to be addressed.
Harnessing the Ability to Persistently Retain Genetic Information for Treatment
The persistence of genetic information—which is a problem in infection—can be an advantage in treatment. This is because if the genes needed for treatment are stably integrated into cells and function properly, there is a possibility that those cells and their descendants will produce the necessary proteins for a long time. One of the tools that utilizes this principle is the “lentiviral vector,” which belongs to the retrovirus family. HIV also belongs to the lentivirus family, and research on its structure and mechanism of action has laid the foundation for the development of such vectors.
Therapeutic vectors do not use the disease-causing virus in its original form. While they utilize the elements necessary for delivering genetic material, they are designed to either remove the genes required for the virus to continue replicating in the patient’s body or to supply those genes separately during the manufacturing process. Therefore, a distinction must be made between the fact that elements derived from HIV are used and the idea that the treatment causes HIV infection in the patient.
Gene therapy involves either delivering the vector directly into the patient’s body or extracting cells from the body, genetically modifying them, and then re-administering them. When cells are modified outside the body, the necessary cells are collected, the therapeutic gene is delivered, quality standards are verified, and the cells are then returned to the patient. However, not all gene therapies use viruses, nor does the delivered gene necessarily integrate into the host genome. The delivery method and mechanism of action vary depending on the disease and the target cells.
An example of an actual treatment is Zynteglo, which was approved by the U.S. Food and Drug Administration (FDA) in 2022. It is a gene therapy for adults and children with beta-thalassemia who require regular red blood cell transfusions. Beta-thalassemia is a genetic disorder in which beta-globin—a component of hemoglobin, the protein that carries oxygen—is not produced in sufficient quantities. Zynteglo uses a lentiviral vector to introduce a modified gene capable of producing functional beta-globin into hematopoietic stem cells collected from the patient. Hematopoietic stem cells are the source cells that give rise to various types of blood cells. When the genetically modified cells are reinfused, they settle in the bone marrow and help produce red blood cells containing therapeutic hemoglobin.
However, the fact that the gene is integrated into the genome is both an advantage and a risk factor. Depending on the insertion site, the activity of surrounding genes may change, and if the mechanisms regulating cell proliferation are disrupted, this could lead to a risk of tumor development. For this reason, success cannot be judged based solely on the immediate effects following treatment. The FDA approval document for Zynteglo also warns of the potential risk of cancer associated with gene insertion and requires long-term monitoring. Even if a method is useful for a specific disease, it does not guarantee the same efficacy and safety for other diseases.
To draw an analogy with computer hacking, a virus exploits a cell’s information processing and production systems to achieve its desired outcome. Gene therapy is a technology that understands this mechanism of action and redesigns the information to be delivered to suit therapeutic purposes. The key here is not merely which gene is inserted. We must also consider which cells to target, how long and to what extent the gene should function, and what risks may arise during that process. The concept of using cells as factories to produce therapeutic proteins has already become a reality. To further expand this potential, we need the ability to precisely manage post-delivery function and safety just as much as the ability to deliver genetic information.